A phase I study of PXL 770 in healthy volunteers

Trial Profile

A phase I study of PXL 770 in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs PXL 770 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Proof of concept
  • Sponsors Poxel
  • Most Recent Events

    • 20 Sep 2017 According to a Poxel media release, the company has initiated a multiple ascending dose (MAD) trial for PXL770 and subjects have been dosed. The MAD trial will include up to 76 subjects and evaluate the safety, tolerability and pharmacokinetics of PXL770 in at least four dose groups. Completion of the MAD trial is anticipated in early 2018.
    • 03 Apr 2017 According to a Poxel media release, company plans to initiate the multiple ascending dose portion of the Phase 1 study during the second half of 2017.
    • 27 Jan 2017 According to a Poxel media release, the company anticipates to continue the study during the second half of this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top